RT Journal Article
SR Electronic
T1 Analysis of Mesencephalic Astrocyte-derived Neurotrophic Factor in Multiple Myeloma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4305
OP 4312
DO 10.21873/anticanres.15235
VO 41
IS 9
A1 AMANDINE DERNONCOURT
A1 CHLOE SAUZAY
A1 JEAN SCHMIDT
A1 CHRISTOPHE LOUANDRE
A1 CATHY GOMILA
A1 PIERRE DUHAUT
A1 YVES-EDOUARD HERPE
A1 ZUZANA SAIDAK
A1 ANTOINE GALMICHE
A1 VALERY SALLE
YR 2021
UL http://ar.iiarjournals.org/content/41/9/4305.abstract
AB Background/Aim: Multiple myeloma (MM) is characterized by high production of immunoglobulins resulting in a constant source of endoplasmic reticulum (ER)-stress. Mesencephalic astrocyte-derived neurotrophic factor (MANF) was identified as a possible circulating biomarker that could help in monitoring ER-stress mediated diseases. Materials and Methods: To assess the relevance of MANF in MM, we performed in silico and in vitro analysis in malignant cell lines including the myeloma cell line RPMI 8226. Serum MANF concentration was compared between healthy subjects (n=60), patients with MM (n=68), or those with monoclonal gammopathy of undetermined significance (MGUS) (n=73). Results: MANF mRNA expression was upregulated in the RPMI 8226 cell line, and higher secretion of MANF was measured in RPMI 8226 supernatant. Serum MANF levels were not significantly different between MM or MGUS patients and those in age- and sex-matched healthy controls. Conclusion: MANF was not validated as a biomarker of interest in MM patients. Its potential implication in myeloma pathogenesis should be investigated.